AR and neoplasm: We plan to further investigate loss of AR expression as a potential mechanism of acquired resistance in AR positive TNBC through the development of additional AR positive TNBC PDX models and testing for AR in tumor tissue samples obtained from patients treated with ENMD-2076 in an ongoing Phase II clinical trial in metastatic previously treated TNBC (NCT01639248).